Predict your next investment

Corporation
actuate.plus

See what CB Insights has to offer

Investments

1

About Actuate

Actuate is a part of an affiliate acting on Europe and Turkey; focused on transforming ideas into innovative products and services; accelerating growth with innovation and entrepreneurship. The company has two acting arms: Actuate.Plus and Actuate.Solutions. Actuate.Plus targets acceleration of innovation and entrepreneurial growth; whereas Actuate.Solutions aims to actualize innovative technologies and corporate solutions according to customer needs.

Actuate Headquarter Location

Büyükdere Cad. Ecza Sok. No:4/1, Şişli

Istanbul, 34394,

Turkey

+90 212 705 62 12

Predict your next investment

The CB Insights tech market intelligence platform analyzes millions of data points on venture capital, startups, patents , partnerships and news mentions to help you see tomorrow's opportunities, today.

Research containing Actuate

Get data-driven expert analysis from the CB Insights Intelligence Unit.

CB Insights Intelligence Analysts have mentioned Actuate in 1 CB Insights research brief, most recently on Oct 1, 2020.

Latest Actuate News

Actuate Therapeutics Announces FDA Fast Track Designation for 9-ING-41 for Treatment of Pancreatic Cancer

Aug 16, 2021

By Actuate Therapeutics, Inc. Sign up for our free Email Newsletter Success! An email has been sent to with a link to confirm list signup. Error! There was an error processing your request. Neighbor Newspapers News Updates Sign up CHICAGO, and FORT WORTH, Texas, Aug. 5, 2021 /PRNewswire-PRWeb/ -- Actuate Therapeutics, Inc. (Actuate), a clinical stage biopharmaceutical company, today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track Designation for 9-ING-41 for treatment of patients with pancreatic cancer. 9-ING-41 is Actuate's proprietary small molecule glycogen synthase kinase-3 beta (GSK-3β) inhibitor which is being developed for adults and children with advanced refractory cancers. "We are pleased with the FDA's decision to grant Fast Track Designation to 9-ING-41 for the treatment of pancreatic cancer. Pancreatic cancer remains an area of high unmet medical need, with less than 10% survival in the US at 5 years. The Fast Track Designation, along with the initiation of our new randomized controlled Phase 2 study protocol for frontline treatment of metastatic pancreatic cancer, further our ability to advance development and regulatory interactions with the FDA to bring 9-ING-41 to patients with this highly lethal malignancy", said Daniel Schmitt, President & CEO. The FDA's Fast Track program is designed to facilitate the expedited development of drugs to treat serious conditions and unmet medical needs. The Fast Track Designation will allow Actuate to have more frequent FDA interactions related to the 9-ING-41 drug development program as well as rolling review, and potentially priority review, of the company's NDA marketing application. Actuate first enrolled patients with advanced pancreatic cancer on a phase 2 study of 9-ING-41 combined with gemcitabine/nab-paclitaxel, as an additional arm of the ongoing phase 1/2 1801 trial of 9-ING-41, (NCT03678883, EudraCT#:2018-003739-32). "Based on the initial data from our ongoing single arm study, we have initiated a randomized Phase 2 study for frontline treatment of patients with metastatic pancreatic cancer" said Dr. Francis Giles, Actuate's Chief Medical Officer. "Patients will be randomized to 9-ING-41 in combination with gemcitabine/nab-paclitaxel versus gemcitabine/nab-paclitaxel alone. We are also working with lead investigators to launch additional clinical studies of 9-ING-41 for front line treatment of pancreatic cancer in combination with a checkpoint inhibitor and with the FOLFIRINOX regimen". Actuate is also recruiting patients for their 1901 international phase 2 study of 9-ING-41 as a single agent and in combination with Ruxolitinib in patients with advanced refractory myelofibrosis, (NCT04218071), and for study 1902 international Phase 1 study as a single agent or with irinotecan, irinotecan plus temozolomide, or with cyclophosphamide plus topotecan in pediatric patients with refractory malignancies, (NCT04239092). In addition, investigators at the Dana Farber Cancer Institute are initiating a clinical study of 9-ING-41 in combination with carboplatin in patients with incurable, recurrent or metastatic salivary gland carcinomas and investigators at Brown University are developing a clinical study of 9-ING-41 in combination with gemcitabine and docetaxel in patients with refractory sarcomas. An extension arm of the 1801 trial will examine the activity of 9-ING-41 in patients with refractory Adult T-cell Leukemia/Lymphoma. About Actuate Therapeutics, Inc. Actuate is a clinical stage pharmaceutical company focused on the development and commercialization of novel therapeutics for cancers and inflammatory diseases. For additional information, please visit the Company's website at http://www.actuatetherapeutics.com Media Contact

Actuate Investments

1 Investments

Actuate has made 1 investments. Their latest investment was in AppButiq as part of their Corporate Minority on January 1, 2019.

CBI Logo

Actuate Investments Activity

investments chart

Date

Round

Company

Amount

New?

Co-Investors

Sources

1/2/2019

Corporate Minority

AppButiq

Yes

2

Date

1/2/2019

Round

Corporate Minority

Company

AppButiq

Amount

New?

Yes

Co-Investors

Sources

2

Actuate Team

1 Team Member

Actuate has 1 team member, including undefined undefined, undefined.

Name

Work History

Title

Status

Varag Gharibjanian

Founder

Current

Name

Varag Gharibjanian

Work History

Title

Founder

Status

Current

CB Insights uses Cookies

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.